← Leaderboards
Ari M. Melnick
Mount Sinai School Of Medicine Of Nyu
$26,120,182
Attributed
$33,854,908
Total exposure
17
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$33,854,908 · 17
By mechanism
R01$16,465,052 · 8
R35$7,171,325 · 1
P01$3,694,254 · 3
U10$2,999,995 · 1
UG1$2,711,464 · 1
R21$363,900 · 1
Top collaborators
- Ross L Levine7 shared
- Gabriela Chiosis5 shared
- Nathanael Schiander Gray5 shared
- Elisabeth Paietta5 shared
- Hao Wu5 shared
- Adolfo A. Ferrando3 shared
- Omar Abdel-Wahab2 shared
- Olivier Elemento1 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Edward A Fisher$34,926,928
Others in their field
Top investigators on “S Lymphoma”
- David Heimbrook · Leidos Biomedical Research, Inc.$171,980,034
- Richard L Schilsky · University Of Chicago$120,036,663
- Joseph Sparano · Montefiore Medical Center (Bronx, Ny)$113,682,224
- Ronald T Mitsuyasu · University Of California Los Angeles$103,553,444
- Monica M Bertagnolli · Strang Cancer Prevention Center$61,393,123
- Charles A Coltman · Southwest Oncology Group$55,198,633
Research focus
S LymphomaLarge Cell Diffuse Non-Hodgkin&AposB-LymphocytesBaseLymphomaB-Cell LymphomasProgramsBiologicalComplexStructure Of Germinal Center Of Lymph NodeTranslatingInhibitor/AntagonistLeadResponseTherapeutic TargetProteinsClinical TrialsClinicCellsMalignant NeoplasmsDesignSignal TransductionDrug TargetingTumor
Grant awards (67)
Chromatin Architecture Regulatory Mechanisms in Pathogenesis of B-Cell Lymphomas$720,776
P01 · FY2025 · CA · contact PI
Project 1 Melnick$407,046
P01 · FY2025 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$965,684
R35 · FY2024 · CA · contact PI
Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas$645,866
R01 · FY2024 · CA · contact PI
Project 1 Melnick$412,435
P01 · FY2024 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$951,038
R35 · FY2023 · CA · contact PI
Therapeutic targeting of SIRT3 for aggressive and refractory lymphomas$679,859
R01 · FY2023 · CA · contact PI
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia$404,255
P01 · FY2023 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$996,660
R35 · FY2022 · CA · contact PI
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia$489,106
P01 · FY2022 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$1,012,843
R35 · FY2021 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$892,711
UG1 · FY2021 · CA
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia$418,251
P01 · FY2021 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$1,128,045
R35 · FY2020 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$859,607
UG1 · FY2020 · CA
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia$412,505
P01 · FY2020 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$986,490
R35 · FY2019 · CA · contact PI
ECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)$959,146
UG1 · FY2019 · CA
Project 2: The cohesin complex as a tumor suppressor in myeloid leukemia$429,880
P01 · FY2019 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$1,017,000
R35 · FY2018 · CA · contact PI
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2018 · CA
COHESIN REGULATORY PROTEINS AND CHROMOSOMAL ARCHITECTURE IN NORMAL AND MALIGNANT B-CELLS$540,539
R01 · FY2018 · CA · contact PI
Targeting Epigenetic Circuits in B-Cell Lymphomas$113,565
R35 · FY2018 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$699,439
R01 · FY2017 · CA
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2017 · CA
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma$492,647
R01 · FY2017 · CA · contact PI
MALT1 Targeted Therapy for B-Cell Lymphoma$351,713
R01 · FY2017 · CA · contact PI
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma$113,565
R01 · FY2017 · CA · contact PI
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma$44,636
R01 · FY2017 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$700,976
R01 · FY2016 · CA
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2016 · CA
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma$379,082
R01 · FY2016 · CA · contact PI
MALT1 Targeted Therapy for B-Cell Lymphoma$351,713
R01 · FY2016 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$708,042
R01 · FY2015 · CA
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2015 · CA
Targeting the heat shock response for the therapy of DLBCL$492,767
R01 · FY2015 · CA · contact PI
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma$379,082
R01 · FY2015 · CA · contact PI
MALT1 Targeted Therapy for B-Cell Lymphoma$351,713
R01 · FY2015 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$684,151
R01 · FY2014 · CA
ECOG-ACRIN INTEGRATED LEUKEMIA TRANSLATIONAL RESEARCH CENTER$599,999
U10 · FY2014 · CA
Molecular Targeting of Diffuse Large B-cell Lymphoma$502,192
R01 · FY2014 · CA · contact PI
Targeting the heat shock response for the therapy of DLBCL$481,623
R01 · FY2014 · CA · contact PI
Targeting EZH2 in Germinal Center Derived B-Cell Lymphoma$396,457
R01 · FY2014 · CA · contact PI
MALT1 Targeted Therapy for B-Cell Lymphoma$351,713
R01 · FY2014 · CA · contact PI
Transcriptional silencing by the BCL6 oncoprotein$241,708
R01 · FY2014 · CA · contact PI
MALT1 inhibitors for the treatment of chemo-resistant ABC-DLBCL$706,957
R01 · FY2013 · CA
Molecular Targeting of Diffuse Large B-cell Lymphoma$493,670
R01 · FY2013 · CA · contact PI
Targeting the heat shock response for the therapy of DLBCL$474,862
R01 · FY2013 · CA · contact PI
Transcriptional silencing by the BCL6 oncoprotein$235,282
R01 · FY2013 · CA · contact PI
Molecular Targeting of Diffuse Large B-cell Lymphoma$571,087
R01 · FY2012 · CA · contact PI
Targeting the heat shock response for the therapy of DLBCL$514,015
R01 · FY2012 · CA · contact PI
Transcriptional silencing by the BCL6 oncoprotein$256,823
R01 · FY2012 · CA · contact PI
Molecular Targeting of Diffuse Large B-cell Lymphoma$587,846
R01 · FY2011 · CA · contact PI
Targeting the heat shock response for the therapy of DLBCL$541,013
R01 · FY2011 · CA · contact PI
Transcriptional silencing by the BCL6 oncoprotein$258,054
R01 · FY2011 · CA · contact PI
Molecular Targeting of Diffuse Large B-cell Lymphoma$633,103
R01 · FY2010 · CA · contact PI
Transcriptional silencing by the BCL6 oncoprotein$268,277
R01 · FY2010 · CA · contact PI
Trancriptional silencing by the Bcl-6 Oncoprotein$267,478
R56 · FY2009 · CA · contact PI
Transcriptional silencing by the Bcl-6 oncoprotein$259,688
R01 · FY2008 · CA · contact PI
Transcriptional silencing by the Bcl-6 oncoprotein$259,688
R01 · FY2007 · CA · contact PI
Transcriptional silencing by the Bcl-6 oncoprotein$267,444
R01 · FY2006 · CA · contact PI
Transcriptional silencing by the Bcl-6 oncoprotein$273,880
R01 · FY2005 · CA
Transcriptional silencing by the Bcl-6 oncoprotein$273,880
R01 · FY2004 · CA
The BTB pocket as a novel cancer therapy target$165,200
R21 · FY2003 · CA
The BTB pocket as a novel cancer therapy target$198,700
R21 · FY2002 · CA
TRANSCRIPTIONAL REGULATION BY THE PLZF PROTEIN$90,720
K08 · FY2001 · CA
TRANSCRIPTIONAL REGULATION BY THE PLZF PROTEIN$90,720
K08 · FY2000 · CA